Morphine Addiction and Oxidative Stress: The Potential Effects of Thioredoxin-1
Long-term administration of morphine for the management of chronic pain will result in tolerance to its analgesic effect and could even cause drug dependence. Numerous studies have demonstrated significant redox alteration in morphine dependence and addiction. Thioredoxin-1 (Trx-1) play important ro...
Saved in:
Published in | Frontiers in pharmacology Vol. 11; p. 82 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
21.02.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Long-term administration of morphine for the management of chronic pain will result in tolerance to its analgesic effect and could even cause drug dependence. Numerous studies have demonstrated significant redox alteration in morphine dependence and addiction. Thioredoxin-1 (Trx-1) play important roles in controlling the cellular redox balance. In recent years, several recent studies have demonstrated that Trx-1 may be a promising novel therapeutic target for morphine addiction. In this article, we firstly review the redox alteration in morphine addiction. We also summarize the expression and the protective roles of Trx-1 in morphine dependence. We further highlight the protection of geranylgeranylacetone (GGA), a noncytotoxic pharmacological inducer of Trx-1, in morphine-induced conditioned place preference. In conclusion, Trx-1 may be very promising for clinical therapy of morphine addiction in the future. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology Edited by: Juan J. Canales, University of Tasmania, Australia Reviewed by: Cristina Núñez, University of Murcia, Spain; Katia Gysling, Pontifical Catholic University of Chile, Chile |
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2020.00082 |